parallel randomized trial

S003426

Design

Randomized: 79
Start year
Treatment: 24 weeks, follow-up 24 weeks
Countries: Pakistan (1 sites)
Sponsor: (non industry)
Eligibility: adults with type 2 diabetes; HbA1c 6.5 to 8.0 percent; BMI 30 to 35; stable metformin and empagliflozin

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Semaglutide 0.5 mg subcutaneous once weekly Semaglutide 0.5 mg once weekly	metformin 2 g/day and empagliflozin 25 mg/day; lifestyle: standard	38	38
A2	Tirzepatide 5 mg subcutaneous once weekly Tirzepatide 5 mg once weekly	metformin 2 g/day and empagliflozin 25 mg/day; lifestyle: standard	41	41

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Semaglutide 0.5 mg subcutaneous once weekly A1	Tirzepatide 5 mg subcutaneous once weekly A2
age sex:female	mean (years)	47.0	48.0
age sex:male	mean (years)	52.0	50.5
bmi	mean (kg/m2)	33.8	34.2
female	n	22	27
female	percent	57.9	65.9
hba1c	mean (percent)	7.7	7.9

11 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

HbA1c change (3 lines; O01)

Week	Arm	Statistic	Estimate	Events / N	Detail
24	A1	change	-0.9 percent	38	not stated; other; R0040396:Table 2
24	A1 vs A2	md	0.5 percent		not stated; other; R0040396:Table 2
24	A2	change	-1.4 percent	41	not stated; other; R0040396:Table 2

Level 2 or 3 hypoglycemia (participants) (3 lines; O04)

Arm	Statistic	Estimate	Events / N	Detail
A1	events		1 / 38	not stated; safety; R0040396:Table 3
A1 vs A2	or	0.53		not stated; safety; R0040396:Table 3
A2	events		2 / 41	not stated; safety; R0040396:Table 3

Discontinuation due to adverse events (2 lines; O26)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				3 / 38	not stated; safety; R0040396:Abstract
	A2	events				2 / 41	not stated; safety; R0040396:Abstract

Discontinuation due to gastrointestinal adverse events (3 lines; O27E)

Arm	Statistic	Estimate	Events / N	Detail
A1	events		3 / 38	not stated; safety; R0040396:Table 3
A1 vs A2	or	1.67		not stated; safety; R0040396:Table 3
A2	events		2 / 41	not stated; safety; R0040396:Table 3